What is the appropriate treatment for foot psoriasis?

Treatment of Foot Psoriasis

For foot psoriasis, begin with ultrahigh potency (class 1) topical corticosteroids combined with calcipotriene as first-line therapy, and if inadequate response occurs within 4-8 weeks, escalate to systemic therapy with biologics (particularly IL-17 or IL-23 inhibitors) or acitretin, with consideration of phototherapy (soak PUVA) as an intermediate option 1, 2.

Algorithmic Treatment Approach

First-Line: Topical Therapy (4-8 weeks trial)

• Ultrahigh potency topical corticosteroids (Class 1) combined with calcipotriene ointment 1, 3
• Alternative: Add tazarotene gel to the regimen 4
• This combination addresses both inflammation and keratinocyte proliferation
• The 2024 case report 3 demonstrates successful management with topical betamethasone and calcipotriol for plantar lesions

Common pitfall: Foot psoriasis requires more aggressive initial therapy than other body sites due to thick hyperkeratotic plaques. Don't undertreate with mid-potency steroids.

Second-Line: Phototherapy (if topicals fail at 4-8 weeks)

• Soak PUVA is specifically effective for palmoplantar psoriasis 4, 5
• This modality is particularly suited for localized foot involvement before escalating to systemic therapy

Third-Line: Systemic Therapy

Preferred systemic agents for moderate-to-severe foot psoriasis:

1. Biologics (First choice for systemic therapy):

   • IL-17 inhibitors (secukinumab, ixekizumab): Can be continued even for intermediate/high-risk procedures, indicating favorable safety profile 6, 2
   • IL-23 inhibitors: Similar safety advantages 6, 2
   • TNF-α inhibitors (infliximab, adalimumab, etanercept): Infliximab showed successful treatment in 4 patients with severe palmoplantar psoriasis with >50% improvement 7, 2
   • IL-12/23 inhibitor (ustekinumab): Recommended in Singapore guidelines 2

2. Oral retinoids (Acitretin):

   • Particularly useful as it can be safely continued through any surgical procedure 6
   • Historically effective for palmoplantar psoriasis 4
   • Avoid in women of childbearing potential

3. Methotrexate:

   • The 2026 German guideline extensively revised methotrexate guidance 8
   • Can be continued for low-risk procedures 6
   • Consider hepatotoxicity and bone marrow toxicity 4

4. Novel agents:

   • Deucravacitinib (TYK2 inhibitor): Newly approved, incorporated into 2026 guidelines 8
   • Apremilast (PDE-4 inhibitor): Can be safely continued perioperatively 6, 2

Combination Strategies

The AAD-NPF guidelines specifically recommend combining topical therapy with biologics 1:

• Adding ultrahigh potency topical corticosteroid to etanercept (Strength A recommendation)
• Adding calcipotriene/betamethasone to adalimumab to accelerate plaque clearance (Strength B recommendation)
• Any topical corticosteroid can be combined with any biologic (Strength C recommendation)

Calcipotriene can be added to methotrexate (Strength A recommendation) 1

Treatment Goals

• Minimum target: PASI 75 response
• Desirable goals: PASI 90 or absolute PASI <2 8

Critical Considerations for Foot Psoriasis

Location-specific challenges:

• Foot psoriasis represents only 2% of body surface area but causes disproportionate disability affecting mobility and dexterity 9
• Hyperkeratosis and fissuring are prominent features requiring aggressive keratolytic therapy initially 7
• Quality of life impairment is severe—patients in the infliximab study 7 were able to resume work responsibilities after treatment

Paradoxical reactions: While TNF-α blockers are effective, rare cases of paradoxical pustular psoriasis induction have been reported with infliximab, warranting cautious use 7. However, the evidence supports their efficacy when benefits outweigh risks.

Psychological comorbidities: Address anxiety and depression, which may exacerbate symptoms 3

Evidence Quality Notes

The strongest guideline evidence comes from the 2021 AAD-NPF joint guidelines 1 with Level I evidence for topical-biologic combinations. The 2026 German S3 guideline 8 and 2024 Singapore guidelines 2 provide the most current systemic therapy recommendations, emphasizing biologics as potential first-line systemic options. Historical evidence for efalizumab 10, 9 is no longer relevant as this agent was withdrawn from the market.